Dovanvetmab Biosimilar – Anti-IL31 mAb – Research Grade

The Structure of Dovanvetmab Biosimilar – Anti-IL31 mAb

Dovanvetmab Biosimilar, also known as Anti-IL31 mAb, is a monoclonal antibody that specifically targets and binds to the cytokine interleukin-31 (IL-31). It is a biosimilar version of the original Dovanvetmab, which was developed as a therapeutic antibody for the treatment of inflammatory skin conditions in dogs. The biosimilar version has been created through a process of recombinant DNA technology, making it identical in structure and function to the original Dovanvetmab.

The structure of Dovanvetmab Biosimilar is composed of two identical heavy chains and two identical light chains, linked together by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL and CL1) and one variable domain (VL). The variable domains are responsible for binding to the target IL-31, while the constant domains provide stability and effector functions.

The Activity of Dovanvetmab Biosimilar

Dovanvetmab Biosimilar exerts its activity by binding to IL-31 and preventing it from interacting with its receptor, IL-31RA, on the surface of cells. IL-31 is a pro-inflammatory cytokine that is primarily produced by activated T cells and plays a key role in the development of skin inflammation and itching. By blocking the interaction between IL-31 and its receptor, Dovanvetmab Biosimilar inhibits the signaling pathway that leads to inflammation and itching.

In addition to its neutralizing activity, Dovanvetmab Biosimilar also has effector functions that contribute to its therapeutic effects. These include antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which involve the recruitment and activation of immune cells to eliminate target cells.

The Application of Dovanvetmab Biosimilar

Dovanvetmab Biosimilar is primarily used as a therapeutic antibody for the treatment of inflammatory skin conditions in dogs, particularly atopic dermatitis. This condition is characterized by chronic inflammation and itching of the skin, which can significantly impact a dog’s quality of life. Dovanvetmab Biosimilar has been shown to effectively reduce skin inflammation and itching in dogs, providing relief and improving their overall well-being.

In addition to its use in dogs, Dovanvetmab Biosimilar has also shown potential for treating other inflammatory conditions in animals. Studies have demonstrated its effectiveness in reducing skin inflammation and itching in cats with allergic dermatitis and horses with insect bite hypersensitivity. Furthermore, Dovanvetmab Biosimilar has also been investigated for its potential in human medicine, particularly for the treatment of atopic dermatitis and other inflammatory skin diseases.

Conclusion

Dovanvetmab Biosimilar, or Anti-IL31 mAb, is a monoclonal antibody that specifically targets and neutralizes the pro-inflammatory cytokine IL-31. Its structure is composed of two heavy chains and two light chains, and it exerts its activity by blocking the interaction between IL-31 and its receptor. Dovanvetmab Biosimilar has shown promising results in the treatment of inflammatory skin conditions in dogs and has potential applications in other animal species and human medicine. With its biosimilar version, this therapeutic antibody offers a cost-effective and reliable option for managing skin inflammation and itching in dogs and potentially other animals.